The impact of SGLT2 inhibitors on dementia onset in patients with type 2 diabetes - A meta-analysis of cohort studies.

IF 3.2 2区医学 Q2 ENDOCRINOLOGY & METABOLISM

Neuroendocrinology Pub Date : 2025-01-11 DOI:10.1159/000543533

Jiani Pan, Huiping Yang, Jiatong Lu, Ling Chen, Tian Wen, Shijie Zhao, Liye Shi

{"title":"The impact of SGLT2 inhibitors on dementia onset in patients with type 2 diabetes - A meta-analysis of cohort studies.","authors":"Jiani Pan, Huiping Yang, Jiatong Lu, Ling Chen, Tian Wen, Shijie Zhao, Liye Shi","doi":"10.1159/000543533","DOIUrl":null,"url":null,"abstract":"Introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated neuroprotective effects and hold potential advantages in enhancing cognitive function. This study aims to clarify the association between SGLT2 inhibitors and the risk of dementia among individuals diagnosed with type 2 diabetes (T2D).Methods: All cohort studies concerning the impact of SGLT2 inhibitors on dementia onset in patients with T2D were identified. The literature search encompassed PubMed, Embase, Cochrane Library, and Web of Science from establishment to Mar 2024, with no language restriction. The quality of the literature was evaluated using the Newcastle-Ottawa Scale (NOS). Meta-analysis was conducted using RevMan5.4 software, calculating pooled risk ratios (RRs) with 95% confidence intervals (CI) for dichotomous outcomes.Results: Five cohort studies encompassing a total of 331908 patients were included in the analysis. The findings showed that individuals receiving SGLT2 inhibitors had a lower risk of dementia (I2 = 42%, P = 0.14; RR: 0.77; 95% CI: 0.71-0.84) compared to the control group. Subgroup analyses confirmed the consistent beneficial effects of SGLT2 inhibitors across different study regions (I2=0%, P=0.60) and genders (I2=0%, P=0.50).Conclusions: SGLT2 inhibitors may reduce the dementia risk in T2D patients. Given the limitations of the study, further investigations were warranted to confirm the benefits.","PeriodicalId":19117,"journal":{"name":"Neuroendocrinology","volume":" ","pages":"1-14"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroendocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000543533","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated neuroprotective effects and hold potential advantages in enhancing cognitive function. This study aims to clarify the association between SGLT2 inhibitors and the risk of dementia among individuals diagnosed with type 2 diabetes (T2D).

Methods: All cohort studies concerning the impact of SGLT2 inhibitors on dementia onset in patients with T2D were identified. The literature search encompassed PubMed, Embase, Cochrane Library, and Web of Science from establishment to Mar 2024, with no language restriction. The quality of the literature was evaluated using the Newcastle-Ottawa Scale (NOS). Meta-analysis was conducted using RevMan5.4 software, calculating pooled risk ratios (RRs) with 95% confidence intervals (CI) for dichotomous outcomes.

Results: Five cohort studies encompassing a total of 331908 patients were included in the analysis. The findings showed that individuals receiving SGLT2 inhibitors had a lower risk of dementia (I2 = 42%, P = 0.14; RR: 0.77; 95% CI: 0.71-0.84) compared to the control group. Subgroup analyses confirmed the consistent beneficial effects of SGLT2 inhibitors across different study regions (I2=0%, P=0.60) and genders (I2=0%, P=0.50).

Conclusions: SGLT2 inhibitors may reduce the dementia risk in T2D patients. Given the limitations of the study, further investigations were warranted to confirm the benefits.

查看原文本刊更多论文

SGLT2抑制剂对2型糖尿病患者痴呆发病的影响——队列研究的荟萃分析

钠-葡萄糖共转运蛋白2 （SGLT2）抑制剂已被证明具有神经保护作用，并在增强认知功能方面具有潜在优势。本研究旨在阐明SGLT2抑制剂与2型糖尿病（T2D）患者痴呆风险之间的关系。方法：确定所有关于SGLT2抑制剂对T2D患者痴呆发病影响的队列研究。文献检索包括PubMed， Embase， Cochrane Library和Web of Science，从成立到2024年3月，没有语言限制。采用纽卡斯尔-渥太华量表（NOS）评价文献的质量。采用RevMan5.4软件进行meta分析，计算二分类结果的合并风险比（rr）， 95%置信区间（CI）。结果：5项队列研究共纳入331908例患者。研究结果显示，接受SGLT2抑制剂的个体患痴呆的风险较低(I2 = 42%, P = 0.14；RR: 0.77;95% CI: 0.71-0.84)。亚组分析证实了SGLT2抑制剂在不同研究区域（I2=0%， P=0.60）和性别（I2=0%， P=0.50）的一致有益效果。结论：SGLT2抑制剂可降低T2D患者痴呆风险。鉴于这项研究的局限性，有必要进一步调查以证实其益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuroendocrinology 医学-内分泌学与代谢

CiteScore

8.30

自引率

2.40%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Neuroendocrinology'' publishes papers reporting original research in basic and clinical neuroendocrinology. The journal explores the complex interactions between neuronal networks and endocrine glands (in some instances also immunecells) in both central and peripheral nervous systems. Original contributions cover all aspects of the field, from molecular and cellular neuroendocrinology, physiology, pharmacology, and the neuroanatomy of neuroendocrine systems to neuroendocrine correlates of behaviour, clinical neuroendocrinology and neuroendocrine cancers. Readers also benefit from reviews by noted experts, which highlight especially active areas of current research, and special focus editions of topical interest.